Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4+CD25 T cells. In patients with advanced melanoma, anti-CTLA-4 antibody therapy achieves cancer regression in 15% of patients. Treatment may be associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and rarely hypophysitis. Many of these toxicities require and respond to brief courses of high-dose corticosteroids. We report on a case of autoimmune hypophysitis with severe clinical symptoms that resolved rapidly after treatment with steroids. It is important to consider both autoimmune hypophysitis and brain metastasis in the differential diagnosis of melanoma patients receiving CTLA-4 blockade who present this constellation of symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e32832e0bffDOI Listing

Publication Analysis

Top Keywords

autoimmune hypophysitis
12
anti-ctla-4 therapy-related
4
autoimmune
4
therapy-related autoimmune
4
hypophysitis
4
hypophysitis melanoma
4
melanoma patient
4
patient cytotoxic
4
cytotoxic t-lymphocyte-associated
4
t-lymphocyte-associated antigen-4
4

Similar Publications

Introduction: Endocrine paraneoplastic syndromes (ePNS) are caused by malignant cells that induce hormonal alterations unrelated to the tissue of origin of the neoplasm. The aim of this manuscript is to review the pathophysiology, diagnosis, and treatment of endocrine paraneoplastic syndromes (ePNS).

Areas Covered: We searched the PubMed/Medline, Embase, and Scielo databases, including 96 articles.

View Article and Find Full Text PDF

 Pituitary adenoma is the most common disease that affects the gland and may be classified as functional/nonsecretory tumors. Inflammatory/infective causes may also affect the pituitary gland. The 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) may have an incremental value in assessing these lesions and in determining their clinical significance.

View Article and Find Full Text PDF
Article Synopsis
  • - Immune checkpoint inhibitors, like pembrolizumab used in melanoma treatment, can cause rare autoimmune reactions affecting endocrine glands, leading to conditions like hyperthyroidism and hypothyroidism.
  • - A 39-year-old man experienced a sequence of endocrine issues following his pembrolizumab treatment, including thyrotoxicosis, hypothyroidism, and central adrenal insufficiency.
  • - This case highlights the need for careful monitoring of hormonal functions in patients undergoing immunotherapy due to the variability and unusual nature of these endocrine side effects.
View Article and Find Full Text PDF
Article Synopsis
  • This systematic review investigates recent cases of hypophysitis—an inflammation of the pituitary gland—in patients who have recovered from COVID-19.
  • Seven cases were studied, mainly involving young adults, with symptoms like headaches and increased thirst, emerging 2-3 weeks after COVID-19 symptoms.
  • The findings showed various imaging results, with some patients receiving glucocorticoid treatment, but long-term follow-up data was limited, highlighting the rarity and unique presentation of COVID-related hypophysitis.
View Article and Find Full Text PDF

Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!